^
Association details:
Biomarker:MYC rearrangement + LDH elevation
Cancer:Diffuse Large B Cell Lymphoma
Regimen:R-CHOP (cyclophosphamide + doxorubicin hydrochloride + + Rituxan (rituximab) + vincristine)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C3 – Early Trials
Source:
Title:

NO DIFFERENCE IN OVERALL SURVIVAL BETWEEN R-CHOP AND R-EPOCH AMONG PATIENTS WITH ADVANCED STAGE MYC-REARRANGED, DOUBLE HIT, OR TRIPLE HIT DIFFUSE LARGE B-CELL LYMPHOMA

Published date:
05/12/2021
Excerpt:
Only patients with MYC-R/DHL/THL who received R-CHOP or R-EPOCH as a first-line therapy were included in the analysis…. Among entire MYC-R cohort, univariate analysis of treatment type (R-CHOP, R-EPOCH), age ≥60y, sex, race, ECOG ≥2, elevated LDH, and >1 extra-nodal site, only ECOG ≥2 (p = <0.001) and elevated LDH (p = 0.041) were significant for worse mortality. By multivariate analysis, ECOG ≥2 (HR 2.59 [1.317-5.1]) and elevated LDH (HR 1.61 [1.016-2.6]) were again the only significant variables associated with risk of mortality.